193 related articles for article (PubMed ID: 31985314)
1. Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis.
Sher AF; Golshani GM; Wu S
Cancer Invest; 2020 Feb; 38(2):130-138. PubMed ID: 31985314
[No Abstract] [Full Text] [Related]
2. Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis.
Wang Z; Yang X; Wang J; Wang S; Mao X; Li M; Zhao Y; Wang W; Qi X; Wu T
J Cancer Res Ther; 2019; 15(7):1435-1449. PubMed ID: 31939421
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
4. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.
Cao M; Li F; Wang Y; Zhang J
Invest New Drugs; 2017 Dec; 35(6):834-838. PubMed ID: 28936569
[TBL] [Abstract][Full Text] [Related]
6. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials.
Li X; Shan BE; Wang J; Xing LP; Guo XJ; Zhang YH; Shi PH; Wang ZY
PLoS One; 2013; 8(11):e81897. PubMed ID: 24312376
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
9. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events.
Zhao B; Zhao H; Zhao J
J Immunother Cancer; 2018 Oct; 6(1):101. PubMed ID: 30285872
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Robert C; Hwu WJ; Hamid O; Ribas A; Weber JS; Daud AI; Hodi FS; Wolchok JD; Mitchell TC; Hersey P; Dronca R; Joseph RW; Boutros C; Min L; Long GV; Schachter J; Puzanov I; Dummer R; Lin J; Ibrahim N; Diede SJ; Carlino MS; Joshua AM
Eur J Cancer; 2021 Feb; 144():182-191. PubMed ID: 33360855
[TBL] [Abstract][Full Text] [Related]
11. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
Gyawali B; Shimokata T; Ando M; Honda K; Ando Y
Ann Oncol; 2017 Feb; 28(2):246-253. PubMed ID: 27771613
[TBL] [Abstract][Full Text] [Related]
12. Risk of treatment-related mortality with sorafenib in patients with cancer.
Zhang XJ; Zhang TY; Yu FF; Wei X; Li YS; Xu F; Wei LX; He J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6681-6. PubMed ID: 24377588
[TBL] [Abstract][Full Text] [Related]
13. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
Costa R; Carneiro BA; Agulnik M; Rademaker AW; Pai SG; Villaflor VM; Cristofanilli M; Sosman JA; Giles FJ
Oncotarget; 2017 Jan; 8(5):8910-8920. PubMed ID: 27852042
[TBL] [Abstract][Full Text] [Related]
14. Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.
Qi WX; Tang LN; Shen Z; Yao Y
Eur J Clin Pharmacol; 2014 Apr; 70(4):461-7. PubMed ID: 24390630
[TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Wu J; Qiu K; Zhu J; Li J; Lin Y; He Z; Li G
Breast; 2015 Dec; 24(6):699-704. PubMed ID: 26376461
[TBL] [Abstract][Full Text] [Related]
17. Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yu X; Zhang X; Yao T; Zhang Y; Zhang Y
Front Med (Lausanne); 2021; 8():627089. PubMed ID: 33659263
[No Abstract] [Full Text] [Related]
18. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Tsai FP; Wu TW
Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
[TBL] [Abstract][Full Text] [Related]
19. Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Jiang Y; Zhang N; Pang H; Gao X; Zhang H
Ther Clin Risk Manag; 2019; 15():293-302. PubMed ID: 30858709
[TBL] [Abstract][Full Text] [Related]
20. Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis.
Abdel-Rahman O
Immunotherapy; 2019 Apr; 11(6):543-554. PubMed ID: 31135244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
